Related references
Note: Only part of the references are listed.Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: A dose-escalation study
Chris Twelves et al.
EUROPEAN JOURNAL OF CANCER (2008)
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer
Henry L. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Selective estrogen-receptor modulators and antihormonal resistance in breast cancer
V. Craig Jordan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cellular responses to EGFR inhibitors and their relevance to cancer therapy
Pinaki R. Dutta et al.
CANCER LETTERS (2007)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith et al.
LANCET (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
F. Ciardiello et al.
BRITISH JOURNAL OF CANCER (2006)
Bidirectional cross talk between ERα and EGFR signalling pathways regulates tamoxifen-resistant growth
D. J. Britton et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
GE Konecny et al.
CANCER RESEARCH (2006)
Lapatinib: Current status and future directions in breast cancer
Beverly Moy et al.
ONCOLOGIST (2006)
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
WL Xia et al.
ONCOGENE (2005)
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
HA Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
M Marty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Overview of tyrosine kinase inhibitors in clinical breast cancer
A Agrawal et al.
ENDOCRINE-RELATED CANCER (2005)
Aromatase inhibitors: Combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance
SRD Johnston et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2005)
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
NL Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A basic peptide within the juxtamembrane region is required for EGF receptor dimerization
S Aifa et al.
EXPERIMENTAL CELL RESEARCH (2005)
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
ER Wood et al.
CANCER RESEARCH (2004)
Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
J Shou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor
ER Levin
MOLECULAR ENDOCRINOLOGY (2003)
Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies
RB Lichtner
BIOMEDICINE & PHARMACOTHERAPY (2003)
Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α
TPJ Garrett et al.
CELL (2002)
Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains
H Ogiso et al.
CELL (2002)
Cellular functions of plasma membrane estrogen receptors
ER Levin
STEROIDS (2002)
Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer
S Tsutsui et al.
BREAST CANCER RESEARCH AND TREATMENT (2002)
Share Paper
